Clinical Trial Update: An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease [Phase 2]

View source ↗

Summary

Open-label Phase II study evaluating topical sirolimus for refractory oral chronic graft-versus-host disease; the trial has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Oral Mucosal Disease Due to Graft-versus-host Disease

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Chronic Graft-versus-Host-Disease, Oral Mucosal Disease Due to Graft-versus-host Disease | Phase 2 | Status: TERMINATED | Results posted: 2018-07-24